SABS Insider Trading Activity and SEC Form 4 Filings
SABS insider trading summary
No open-market insider purchases or sales of SAB Biotherapeutics, Inc. (SABS) have been reported on SEC Form 4 in the past 12 months.
Latest SABS insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Dec 7, 2023 | Eddie Joe Sullivan | Chief Executive Officer | Buy | $2K (1,740 @ $0.88) |
| Nov 30, 2023 | Michael King | Chief Financial Officer | Buy | $5K (5,000 @ $0.90) |
| Nov 29, 2023 | Samuel J Reich | Executive Chairman | Buy | $10K (11,000 @ $0.89) |
| Sep 13, 2022 | Christine E Hamilton | Director | Buy | $7K (10,000 @ $0.73) |
| Sep 7, 2022 | Eddie Joe Sullivan | Chief Executive Officer | Buy | $10K (14,000 @ $0.74) |
| Oct 26, 2021 | Russell P Beyer | Chief Financial Officer | Sell | $2K (278 @ $7.90) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.